RUN vs TARS · P/E 6.0, rev $2.04B vs rev $183.0M
Sunrun Inc (RUN) versus Tarsus Pharmaceuticals Inc (TARS) — a side-by-side from cached financials, not a winner call.
Sunrun Inc (RUN) is a solar company listed on NASDAQ.
Tarsus Pharmaceuticals Inc (TARS) is a biotechnology company listed on NASDAQ.
Latest reported RUN revenue for 2024-12-31 was $2.04B. Net income was -$4.36B. Revenue was down 9.8% from 2023-12-31 to 2024-12-31. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
Latest reported TARS revenue for 2024-12-31 was $183.0M. Net income was -$115.6M. Revenue was up 948.6% from 2023-12-31 to 2024-12-31. TARS currently screens at market cap $2.66B.
RUN currently screens at market cap $3.05B and trailing P/E 6.0. TARS currently screens at market cap $2.66B.
Not investment advice. Open the RUN and TARS stock pages for the full models.
Not investment advice.